Chapter 355 - 236: High-level Medical College Builder

Chapter 355: Chapter 236: High-level Medical College Builder

"In our Xianglin City’s top hepatic tumor surgery departments, the Perfect Triple Method auxiliary technology integrated equipment system, a commercial product from Wu’s Pharmaceutical Company, has already been widely adopted."

"It’s nothing less than a technological revolution in hepatic tumor resection!"

"I can’t believe it’s only been a few days, and he’s already made such deep progress in the third phase of new drug development."

"Simply amazing. It looks like after this conference, I’ll have to take my hospital’s team to Fan City for a visit and bring this brand-new equipment system to our department."

As he watched the doctors in the field of hepatobiliary surgery cheer, applaud, and even make plans for on-site visits to acquire the advanced equipment, Scholar Jiang felt a pang of envy.

He was currently in charge of a major national project under the "14th Five-Year Plan": *Research on the Application of Hybrid Technology in Cardiovascular Surgery*.

The scope and content of this project were even larger and more complex than Wu Ting’s *Phases One through Four of Radical Treatment Technology for Hepatitis B-related Primary Liver Cancer*.

It also involved improvements to clinical procedures within the discipline, advancements in Surgical Techniques, innovations in related material sciences, and generational upgrades of relevant equipment and instruments.

Watching Wu Ting’s project unfold, Scholar Jiang felt a strong sense of resonance. ’If only my own project could progress like this,’ he thought.

In his own vision for the project, what was needed now was a breakthrough in endovascular stents and an improved aortic valve delivery system.

If they could break through these two hardware-related bottlenecks, the entire project would take a huge leap forward and could be completed within the 14th Five-Year Plan’s timeframe!

Watching Wu Ting shine so brightly in the field of hepatobiliary surgery, Scholar Jiang desperately wished a talent like him would emerge in his own research group.

Someone deeply immersed in clinical practice, a specialist in cutting-edge theory, and well-versed in pharmacology. Even more astonishingly, he could code his own programs and improve core algorithms, comprehensively driving the project’s progress forward.

’He’s truly a rare, all-around talent in the medical field.’

Dean Jiang was already scheming. He had to find a way to lure Wu Ting into the field of cardiovascular surgery.

’Approaching Wu Ting directly myself would be too abrupt,’ he considered. ’But I could have Jiang Ming look for an opportunity.’

With this in mind, Scholar Jiang decided to leave the hepatobiliary surgeons to their excitement and go chat with the cardiovascular experts to seek some inspiration.

Just then, however, Wu Ting began to introduce his second research achievement.

"Ladies and gentlemen, if I could have your attention. I will now present the paper on my second achievement."

"This achievement came about through a series of coincidences. First, a friend of mine developed a related condition, which prompted me to pursue advanced training in cardiac stent intervention surgery at the cardiovascular department of Jinggang University Affiliated First Hospital. Second, our emergency department happened to admit a patient with an acute myocardial infarction, whom I was involved in resuscitating..."

"Afterward, I was talking with the patient and discovered, quite coincidentally, that he was the chief engineer for Fan City’s Weixing Petrochemical Group. His area of research was the field of bioabsorbable materials."

"As a surgeon in the hepatobiliary field, I had naturally studied Scholar Zeng’s video courses and understood the importance and foresight of interdisciplinary research. By analyzing the common causes of death in patients with cardiovascular and cerebrovascular diseases, I discovered that the endovascular stents currently on the market have inherent flaws and problems..."

Hearing Wu Ting’s words, a surprised and delighted Scholar Jiang immediately turned back. He walked directly to the stack of papers Wu Ting had placed on the other end of the table.

It was another paper, already slated for the next issue of *Cell*:

"*The Fourth Technological Revolution—Clinical Application of Bioabsorbable Endovascular Stents*!"

’This is a breakthrough in endovascular stents—the very thing I’ve been desperately searching for!’

As Scholar Jiang eagerly flipped through the pages, Wu Ting began his detailed analysis.

"...Percutaneous coronary intervention is one of the most effective procedures for cardiovascular and cerebrovascular diseases. The endovascular stent is the foundation of this surgery and its most critical component. The stent’s clinical efficacy determines the patient’s long-term prognosis. However, the current third-generation, conventional metal stents are associated with adverse clinical events such as acute vessel occlusion and restenosis..."

"Furthermore, the long-term removal of the stent is another major pain point."

"Therefore, after studying the principles, properties, and the pros and cons of existing vascular stents, I began designing what I envisioned as the ideal bioabsorbable stent."

"I must also thank President Liang of Weixing Petrochemical for his full support. With the help of his company’s brand-new bioabsorbable polymer material, we successfully developed and produced a prototype of this new vascular stent."

On the screen behind him, Wu Ting displayed the all-new, revolutionary fourth-generation bioabsorbable polymer stent, jointly developed by Wu’s Pharmaceutical Company and Weixing Petrochemical Group.

Scholar Jiang excitedly looked up and examined the screen closely.

"...A polymer synthesized from the caprolactone family..."

"...It’s a bioabsorbable material with excellent biocompatibility. It degrades and is absorbed within the body via hydrolysis at a controllable rate, with non-toxic, harmless byproducts..."

"...The drug-eluting mechanism for the biodegradable polymer stent is the same as that of traditional metal stents—it uses antiproliferative immunosuppressants and their derivatives, such as Sirolimus, Novolimus, Everolimus, Paclitaxel, and Rapamycin-related drugs..."

"...This fourth-generation product can significantly inhibit neointimal proliferation and reduce the incidence of in-stent restenosis..."